VAV1 and acute myeloid leukemia: In parallel to the above, we engrafted CD45.2+Vav-cre Tet2fl/flTp53fl/fl mouse AML cells, CRISPR edited with A20-targeting sgRNAs (sgA20#1 or sgA20#2) or nontargeting control sgRNAs, into lethally irradiated CD45.1+ recipient mice with supporting CD45.1+ bone marrow cells (Supplemental Figure 13C).